Somatostatin agonists for treatment of acromegaly

Molecular and Cellular Endocrinology

Volumn 286, Issue 1-2, 2008, Pages 192-198

  Ben Shlomo, Anat ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Acromegaly; Efficacy; Side effects; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; BIOCHEMICAL MARKER; LANREOTIDE AUTOGEL; OCTREOTIDE;

ABDOMINAL PAIN; ACROMEGALY; ALLERGY; AMNESIA; ANOREXIA; ARTICLE; BILIARY TRACT DISEASE; CARDIOVASCULAR SYMPTOM; CHOLELITHIASIS; CLINICAL TRIAL; CONSTIPATION; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FLATULENCE; GLUCOSE METABOLISM; GOITER; HAIR LOSS; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HEMORRHOID; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTHYROIDISM; IRON DEFICIENCY ANEMIA; NAUSEA; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; SINUS BRADYCARDIA; SLEEP APNEA SYNDROME; STEATORRHEA; SYMPTOM; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 43549109282     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.11.024     Document Type: Article

References (64)

1. M. al-Maskari J. Gebbie P. Kendall-Taylor The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly Clin. Endocrinol. (Oxf.) 45 1996 415 421
2. G. Amato G. Mazziotti M. Rotondi S. Iorio M. Doga F. Sorvillo G. Manganella F. Di Salle A. Giustina C. Carella Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly Clin. Endocrinol. (Oxf.) 56 2002 65 71
3. M.R. Ambrosio P. Franceschetti M. Bondanelli M. Doga P. Maffei R. Baldelli G. Tamburrano N. Sicolo A. Giustina E.C. degli Uberti Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly Metabolism 51 2002 387 393
4. R. Attanasio R. Baldelli R. Pivonello S. Grottoli L. Bocca V. Gasco M. Giusti G. Tamburrano A. Colao R. Cozzi Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly J. Clin. Endocrinol. Metab. 88 2003 5258 5265
5. J. Ayuk S.E. Stewart P.M. Stewart M.C. Sheppard Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly J. Clin. Endocrinol. Metab. 87 2002 4142 4146
6. J. Ayuk S.E. Stewart P.M. Stewart M.C. Sheppard Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy Clin. Endocrinol. (Oxf.) 60 2004 375 381
7. R. Baldelli E. Ferretti M.L. Jaffrain-Rea G. Iacobellis G. Minniti B. Caracciolo C. Moroni R. Cassone A. Gulino G. Tamburrano Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients J. Clin. Endocrinol. Metab. 84 1999 527 532
8. R. Baldelli A. Colao P. Razzore M.L. Jaffrain-Rea P. Marzullo E. Ciccarelli E. Ferretti D. Ferone D. Gaia F. Camanni G. Lombardi G. Tamburrano Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg) J. Clin. Endocrinol. Metab. 85 2000 4099 4103
9. R. Baldelli C. Battista F. Leonetti M.R. Ghiggi M.C. Ribaudo A. Paoloni E. D’Amico E. Ferretti R. Baratta A. Liuzzi V. Trischitta G. Tamburrano Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment Clin. Endocrinol. (Oxf.) 59 2003 492 499
10. L.B. Barnard W.G. Grantham P. Lamberton T.M. O’Dorisio I.M. Jackson Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995) Ann. Intern. Med. 105 1986 856 861
11. A. Ben-Shlomo S. Melmed Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly J. Clin. Endocrinol. Metab. 88 2003 963 968
12. J.S. Bevan S.L. Atkin A.B. Atkinson P.M. Bouloux F. Hanna P.E. Harris R.A. James M. McConnell G.A. Roberts M.F. Scanlon P.M. Stewart E. Teasdale H.E. Turner J.A. Wass J.M. Wardlaw Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size J. Clin. Endocrinol. Metab. 87 2002 4554 4563
13. N.R. Biermasz J.A. Romijn A.M. Pereira F. Roelfsema Current pharmacotherapy for acromegaly: a review Expert Opin. Pharmacother. 6 2005 2393 2405
14. M. Bronstein N. Musolino R. Jallad J.M. Cendros J. Ramis R. Obach A. Leselbaum F. Catus Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days Clin. Endocrinol. (Oxf.) 63 2005 514 519
15. D. Bruttomesso C. Fongher B. Silvestri S. Barberio M.C. Marescotti E. Iori A. Valerio D. Crazzolara A. Pianta A. Tiengo S. Del Prato Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients Diabetes Res. Clin. Pract. 51 2001 97 105
16. P. Caron I. Morange-Ramos M. Cogne P. Jaquet Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide J. Clin. Endocrinol. Metab. 82 1997 18 22
17. P. Caron A. Beckers D.R. Cullen M.I. Goth B. Gutt P. Laurberg A.M. Pico M. Valimaki W. Zgliczynski Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly J. Clin. Endocrinol. Metab. 87 2002 99 104
18. P. Caron M. Cogne I. Raingeard V. Bex-Bachellerie J.M. Kuhn Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly Clin. Endocrinol. (Oxf.) 64 2006 209 214
19. J.M. Cendros C. Peraire I.F. Troconiz R. Obach Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel Metabolism 54 2005 1276 1281
20. P. Chanson V. Boerlin C. Ajzenberg Y. Bachelot P. Benito J. Bringer P. Caron B. Charbonnel C. Cortet B. Delemer F. Escobar-Jimenez L. Foubert S. Gaztambide F. Jockenhoevel J.M. Kuhn J. Leclere Y. Lorcy L. Perlemuter H. Prestele P. Roger V. Rohmer R. Santen G. Sassolas W.A. Scherbaum J. Schopohl E. Torres C. Varela F. Villamil S.M. Webb Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly Clin. Endocrinol. (Oxf.) 53 2000 577 586
21. P. Chanson A. Leselbaum J. Blumberg G. Schaison Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly Pituitary 2 2000 269 276
22. A. Colao P. Marzullo D. Ferone L. Spinelli A. Cuocolo D. Bonaduce M. Salvatore V. Boerlin I. Lancranjan G. Lombardi Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly J. Clin. Endocrinol. Metab. 85 2000 3132 3140
23. A. Colao D. Ferone P. Marzullo P. Cappabianca S. Cirillo V. Boerlin I. Lancranjan G. Lombardi Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly J. Clin. Endocrinol. Metab. 86 2001 2779 2786
24. A. Colao L. Spinelli A. Cuocolo S. Spiezia R. Pivonello C. di Somma D. Bonaduce M. Salvatore G. Lombardi Cardiovascular consequences of early-onset growth hormone excess J. Clin. Endocrinol. Metab. 87 2002 3097 3104
25. A. Colao P. Marzullo A. Cuocolo L. Spinelli R. Pivonello D. Bonaduce M. Salvatore G. Lombardi Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide Clin. Endocrinol. (Oxf.) 58 2003 169 176
26. A. Colao D. Ferone P. Marzullo G. Lombardi Systemic complications of acromegaly: epidemiology, pathogenesis, and management Endocr. Rev. 25 2004 102 152
27. A. Colao R. Pivonello R.S. Auriemma F. Briganti M. Galdiero F. Tortora F. Caranci S. Cirillo G. Lombardi Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients J. Clin. Endocrinol. Metab. 91 2006 2112 2118
28. A. Colao E. Martino P. Cappabianca R. Cozzi M. Scanarini E. Ghigo First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group J. Endocrinol. Invest. 29 2006 1017 1020
29. A. Colao R. Pivonello F. Rosato P. Tita E. De Menis A. Barreca R. Ferrara F. Mainini M. Arosio G. Lombardi First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial Clin. Endocrinol. (Oxf.) 64 2006 342 351
30. R. Cozzi D. Dallabonzana R. Attanasio M. Barausse G. Oppizzi A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly Eur. J. Endocrinol. 141 1999 267 271
31. R. Cozzi R. Attanasio M. Montini G. Pagani G. Lasio S. Lodrini M. Barausse M. Albizzi D. Dallabonzana A.M. Pedroncelli Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J. Clin. Endocrinol. Metab. 88 2003 3090 3098
32. R. Cozzi M. Montini R. Attanasio M. Albizzi G. Lasio S. Lodrini P. Doneda L. Cortesi G. Pagani Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage J. Clin. Endocrinol. Metab. 91 2006 1397 1403
33. P.H. Davies S.E. Stewart L. Lancranjan M.C. Sheppard P.M. Stewart Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly Clin. Endocrinol. (Oxf.) 48 1998 311 316
34. L.M. Fatti M. Scacchi E. Lavezzi F.P. Giraldi M. De Martin P. Toja G. Michailidis M. Stramba-Badiale F. Cavagnini Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients Clin. Endocrinol. (Oxf.) 65 2006 626 630
35. A.K. Flogstad J. Halse S. Bakke I. Lancranjan P. Marbach C. Bruns J. Jervell Sandostatin LAR in acromegalic patients: long-term treatment J. Clin. Endocrinol. Metab. 82 1997 23 28
36. P.U. Freda Somatostatin analogs in acromegaly J. Clin. Endocrinol. Metab. 87 2002 3013 3018
37. P.U. Freda L. Katznelson A.J. van der Lely C.M. Reyes S. Zhao D. Rabinowitz Long-acting somatostatin analog therapy of acromegaly: a meta-analysis J. Clin. Endocrinol. Metab. 90 2005 4465 4473
38. M. Giusti G. Gussoni C.M. Cuttica G. Giordano Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group J. Clin. Endocrinol. Metab. 81 1996 2089 2097
39. B. Gutt M. Bidlingmaier K. Kretschmar C. Dieterle B. Steffin J. Schopohl Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel) Exp. Clin. Endocrinol. Diabetes 113 2005 139 144
40. I.M. Holdaway R.C. Rajasoorya G.D. Gamble Factors influencing mortality in acromegaly J. Clin. Endocrinol. Metab. 89 2004 667 674
41. J. Hradec J. Kral T. Janota M. Krsek V. Hana J. Marek M. Malik Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog) Am. J. Cardiol. 83 1999 1506 1509 A8
42. M.S. Ip K.C. Tan W.C. Peh K.S. Lam Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity Clin. Endocrinol. (Oxf.) 55 2001 477 483
43. R.S. Jallad N.R. Musolino L.R. Salgado M.D. Bronstein Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution Clin. Endocrinol. (Oxf.) 63 2005 168 175
44. I. Lancranjan C. Bruns P. Grass P. Jaquet J. Jervell P. Kendall-Taylor S.W. Lamberts P. Marbach H. Orskov G. Pagani M. Sheppard L. Simionescu Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients Metabolism 45 1996 67 71
45. I. Lancranjan A.B. Atkinson Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group Pituitary 1 1999 105 114
46. G. Lombardi A. Colao P. Marzullo B. Biondi E. Palmieri S. Fazio Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study J. Endocrinol. Invest. 25 2002 971 976
47. M.J. Low Clinical endocrinology and metabolism. The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders Best Pract. Res. Clin. Endocrinol. Metab. 18 2004 607 622
48. T. Lucas R. Astorga M. Catala Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage Clin. Endocrinol. (Oxf.) 58 2003 471 481
49. T. Lucas R. Astorga Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial Clin. Endocrinol. (Oxf.) 65 2006 320 326
50. P. Maison A.I. Tropeano I. Macquin-Mavier A. Giustina P. Chanson Impact of somatostatin analogs on the heart in acromegaly. A meta-analysis J. Clin. Endocrinol. Metab. 92 2007 1743 1747
51. J. Marek V. Hana M. Krsek V. Justova F. Catus F. Thomas Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide Eur. J. Endocrinol. 131 1994 20 26
52. K. McKeage S. Cheer A.J. Wagstaff Octreotide long-acting release (LAR): a review of its use in the management of acromegaly Drugs 63 2003 2473 2499
53. S. Melmed F. Casanueva F. Cavagnini P. Chanson L.A. Frohman R. Gaillard E. Ghigo K. Ho P. Jaquet D. Kleinberg S. Lamberts E. Laws G. Lombardi M.C. Sheppard M. Thorner M.L. Vance J.A. Wass A. Giustina Consensus statement: medical management of acromegaly Eur. J. Endocrinol. 153 2005 737 740
54. S. Melmed R. Sternberg D. Cook A. Klibanski P. Chanson V. Bonert M.L. Vance D. Rhew D. Kleinberg A. Barkan A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly J. Clin. Endocrinol. Metab. 90 2005 4405 4410
55. I. Morange F. De Boisvilliers P. Chanson B. Lucas D. DeWailly F. Catus F. Thomas P. Jaquet Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide J. Clin. Endocrinol. Metab. 79 1994 145 151
56. Y.C. Patel Somatostatin and its receptor family Front Neuroendocrinol. 20 1999 157 198
57. C. Rajasoorya I.M. Holdaway P. Wrightson D.J. Scott H.K. Ibbertson Determinants of clinical outcome and survival in acromegaly Clin. Endocrinol. (Oxf.) 41 1994 95 102
58. C. Ronchi P. Epaminonda V. Cappiello P. Beck-Peccoz M. Arosio Effects of two different somatostatin analogs on glucose tolerance in acromegaly J. Endocrinol. Invest. 25 2002 502 507
59. C.L. Ronchi V. Varca P. Beck-Peccoz E. Orsi F. Donadio A. Baccarelli C. Giavoli E. Ferrante A. Lania A. Spada M. Arosio Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors J. Clin. Endocrinol. Metab. 91 2006 121 128
60. P.M. Stewart K.F. Kane S.E. Stewart I. Lancranjan M.C. Sheppard Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly J. Clin. Endocrinol. Metab. 80 1995 3267 3272
61. K.C. Tan R.W. Pang S.C. Tiu K.S. Lam Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly Clin. Endocrinol. (Oxf.) 59 2003 558 564
62. H.E. Turner A. Vadivale J. Keenan J.A. Wass A comparison of lanreotide and octreotide LAR for treatment of acromegaly Clin. Endocrinol. (Oxf.) 51 1999 275 280
63. J.A. Verhelst A.M. Pedroncelli R. Abs M. Montini M.V. Vandeweghe G. Albani D. Maiter M.D. Pagani J.J. Legros D. Gianola M. Bex K. Poppe J. Mockel G. Pagani Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients Eur. J. Endocrinol. 143 2000 577 584
64. G. Weckbecker I. Lewis R. Albert H.A. Schmid D. Hoyer C. Bruns Opportunities in somatostatin research: biological, chemical and therapeutic aspects Nat. Rev. Drug Discov. 2 2003 999 1017